Carbamazepine does not prevent Oxaliplatin-Related Neurotoxicity in Patients with Advanced Colorectal Cancer: Final Results of a Randomised, Controlled, Multicenter Phase II Study
S von Delius, F Eckel, S Wagenpfeil, M Mayr, K Stock, F Kullmann, F Obermeier, J Erdmann, R Schmelz, S Quasthoff, H Adelsberger, RM Schmid, C Lersch · Zeitschrift für Gastroenterologie · 2006 · Heft 10
Bibliografische Angaben
Zusammenfassung
Background: Oxaliplatin-induced neurotoxicity is a growing, relevant clinical problem. In this study we evaluated the efficacy and safety of carbamazepine for prevention of oxaliplatin-associated neuropathy in patients with advanced colorectal cancer. Methods: Chemotherapeutic treatment consisted of oxaliplatin 85mg/m2 given biweekly and weekly folinic acid 500mg/m2 followed by a 24-hour infusion of 5-FU 2000mg/m2 (FUFOX). One cycle consisted of six consecutive weeks of treatment followed by two weeks of rest (=Treatment B). For Treatment A carbamazepine was added in a dosage for targeted plasma levels of 4–6mg/…
